Drugs / CM338
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05371379 | May → Nov 2022 | — | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05186285 | Dec 2021 → Jul 2022 | — | Keymed Biosciences Co.Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05775042 | May 2023 → Jun 2027 expected | IgA glomerulonephritis | Keymed Biosciences Co.Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM338 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05186285 ↗ |
| Modality | Monoclonal antibody | “CM338 : a humanized monoclonal antibody.” NCT05186285 ↗ |
| Route | Intravenous | “CM338 injection administered intravenously or subcutaneously at different doses in healthy subjects.” NCT05186285 ↗ |
| Route | Subcutaneous | “CM338 injection administered intravenously or subcutaneously at different doses in healthy subjects.” NCT05186285 ↗ |